Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-014905
Filing Date
2024-11-07
Accepted
2024-11-07 17:15:37
Documents
85
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q iova-20240930x10q.htm   iXBRL 10-Q 2906751
2 EX-31.1 iova-20240930xex31d1.htm EX-31.1 12341
3 EX-31.2 iova-20240930xex31d2.htm EX-31.2 12228
4 EX-32.1 iova-20240930xex32d1.htm EX-32.1 7108
5 EX-32.2 iova-20240930xex32d2.htm EX-32.2 7173
  Complete submission text file 0001558370-24-014905.txt   10790209

Data Files

Seq Description Document Type Size
6 EX-101.SCH iova-20240930.xsd EX-101.SCH 66863
7 EX-101.CAL iova-20240930_cal.xml EX-101.CAL 62298
8 EX-101.DEF iova-20240930_def.xml EX-101.DEF 291651
9 EX-101.LAB iova-20240930_lab.xml EX-101.LAB 508889
10 EX-101.PRE iova-20240930_pre.xml EX-101.PRE 442275
88 EXTRACTED XBRL INSTANCE DOCUMENT iova-20240930x10q_htm.xml XML 1929027
Mailing Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

EIN.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36860 | Film No.: 241437071
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)